Monday, July 18, 2016

BRIEF-Astrazeneca's lung cancer drug meets primary endpoint in late-stage trial

* Objective response rate, disease control rate, duration of

response achieved clinically meaningful improvement versus

chemotherapy

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)